Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Oregon's state-licensed psilocybin sessions are showing promising results. A new longitudinal study found significant drops in depression, anxiety, and PTSD symptoms — with no serious adverse medical events — among 346 participants over three months. Experts say the findings are encouraging but call for controlled trials before drawing firm clinical conclusions.
Oregon made history in 2020 by becoming the first U.S. state to legalize regulated psilocybin services, and now the data is starting to roll in. A longitudinal cohort study published in JAMA Network Open tracked 346 adults across 24 Oregon psilocybin centers between November 2024 and March 2026, finding meaningful improvements in mental health outcomes with a strong safety profile.
Participants reported significant reductions in moderate-to-severe depression, anxiety, and PTSD symptoms over three months, alongside gains in mental well-being and life satisfaction. Retention rates stayed above 90% throughout the study, and 92.2% of participants said they benefited from the experience. Notably, no serious adverse medical events occurred, though four sessions resulted in serious behavioral reactions — all in first-time psychedelic users.
Experts urge caution, however. The study lacked a control group, and roughly half the participants had prior psilocybin experience — a factor that may have skewed safety and efficacy results toward a more favorable outcome.
By the Numbers:
Why it matters: This is one of the first real-world datasets from a state-regulated psychedelic program, offering a glimpse into how psilocybin performs outside of clinical trials. While the results are promising, researchers stress the need for randomized controlled studies to confirm whether these benefits hold up in broader, more diverse clinical populations.
